While immunosuppressive markers, such as PD-1/PD-L1, were more prevalent in patients with active disease than in NED following therapy or NDs, it remained unclear whether they vary in the course of disease progression or could indicate tumor recovery. This evidence concerns the gene CD274 and neoplasm.